Michael B. Livingston

2.1k total citations · 1 hit paper
28 papers, 1.3k citations indexed

About

Michael B. Livingston is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Michael B. Livingston has authored 28 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pulmonary and Respiratory Medicine, 16 papers in Oncology and 7 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Michael B. Livingston's work include Sarcoma Diagnosis and Treatment (19 papers), Vascular Tumors and Angiosarcomas (9 papers) and Cardiac tumors and thrombi (7 papers). Michael B. Livingston is often cited by papers focused on Sarcoma Diagnosis and Treatment (19 papers), Vascular Tumors and Angiosarcomas (9 papers) and Cardiac tumors and thrombi (7 papers). Michael B. Livingston collaborates with scholars based in United States, United Kingdom and Ukraine. Michael B. Livingston's co-authors include Matthew M. Cooney, Anthony Elias, Gary K. Schwartz, Robert G. Maki, Mark Agulnik, Scott M. Schuetze, Samir D. Undevia, Mary Louise Keohan, David R. D’Adamo and Robin L. Jones and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Michael B. Livingston

27 papers receiving 1.3k citations

Hit Papers

Olaratumab and doxorubici... 2016 2026 2019 2022 2016 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
    2016 436 citations William D. Tap, Robin L. Jones et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael B. Livingston United States 13 1.0k 793 358 234 172 28 1.3k
Breelyn A. Wilky United States 22 977 1.0× 912 1.2× 280 0.8× 220 0.9× 379 2.2× 101 1.7k
Gina Z. D’Amato United States 16 1.0k 1.0× 447 0.6× 165 0.5× 176 0.8× 244 1.4× 75 1.3k
Lorenzo D’Ambrosio Italy 18 777 0.8× 590 0.7× 132 0.4× 171 0.7× 337 2.0× 50 1.2k
Binh Bui Nguyen France 12 1.1k 1.1× 658 0.8× 410 1.1× 196 0.8× 125 0.7× 49 1.3k
Martine Trassard France 19 1.1k 1.1× 839 1.1× 570 1.6× 315 1.3× 259 1.5× 37 1.7k
Veridiana Pires de Camargo Brazil 9 641 0.6× 539 0.7× 207 0.6× 167 0.7× 68 0.4× 26 878
Jonathan Landa United States 13 815 0.8× 597 0.8× 205 0.6× 154 0.7× 178 1.0× 27 1.1k
Claudia Lebedinsky United States 15 693 0.7× 732 0.9× 204 0.6× 252 1.1× 259 1.5× 54 1.5k
Saskia Kropf Germany 20 505 0.5× 886 1.1× 111 0.3× 140 0.6× 235 1.4× 31 1.7k
César Serrano Spain 24 1.3k 1.2× 459 0.6× 174 0.5× 196 0.8× 226 1.3× 103 2.1k

Countries citing papers authored by Michael B. Livingston

Since Specialization
Citations

This map shows the geographic impact of Michael B. Livingston's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael B. Livingston with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael B. Livingston more than expected).

Fields of papers citing papers by Michael B. Livingston

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael B. Livingston. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael B. Livingston. The network helps show where Michael B. Livingston may publish in the future.

Co-authorship network of co-authors of Michael B. Livingston

This figure shows the co-authorship network connecting the top 25 collaborators of Michael B. Livingston. A scholar is included among the top collaborators of Michael B. Livingston based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael B. Livingston. Michael B. Livingston is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Livingston, Michael B., et al.. (2025). Bilateral Achilles Sleeve Avulsions. JBJS Case Connector. 15(4).
2.
Schuetze, Scott M., Michael Rothe, Pam K. Mangat, et al.. (2024). Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology. 8(8). e2400219–e2400219. 2 indexed citations
3.
Attia, Steven, Vanessa Bolejack, Kristen N. Ganjoo, et al.. (2022). A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results. Cancer Medicine. 12(2). 1532–1539. 30 indexed citations
4.
Jagosky, Megan H., Colin J. Anderson, James T. Symanowski, et al.. (2022). Genomic alterations and clinical outcomes in patients with dedifferentiated liposarcoma. Cancer Medicine. 12(6). 7029–7038. 3 indexed citations
5.
Meric‐Bernstam, Funda, Michael Rothe, Elizabeth Garrett‐Mayer, et al.. (2022). Cobimetinib plus vemurafenib (C+V) in patients (Pts) with solid tumors with BRAF V600E/d/k/R mutation: Results from the targeted agent and profiling utilization registry (TAPUR) study.. Journal of Clinical Oncology. 40(16_suppl). 3008–3008. 7 indexed citations
6.
Livingston, Michael B., Megan H. Jagosky, Myra Robinson, et al.. (2020). A pilot study evaluating the safety, tolerability, and efficacy of doxorubicin and pembrolizumab in patients with metastatic or unresectable soft tissue sarcoma.. Journal of Clinical Oncology. 38(15_suppl). 11519–11519. 4 indexed citations
7.
Davis, Lara E., Vanessa Bolejack, Christopher W. Ryan, et al.. (2019). Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. Journal of Clinical Oncology. 37(16). 1424–1431. 174 indexed citations
8.
Chawla, Sant P., Brian Andrew Van Tine, Seth M. Pollack, et al.. (2019). A phase II randomized study of CMB305 and atezolizumab versus atezolizumab in NY-ESO-1+ soft tissue sarcoma: Analysis of immunogenicity, tumor control, and patient survival.. Journal of Clinical Oncology. 37(15_suppl). 11011–11011. 10 indexed citations
9.
Chawla, Sant P., Brian A. Van Tine, Seth M. Pollack, et al.. (2017). A phase 2 study of CMB305 and atezolizumab in NY-ESO-1+ soft tissue sarcoma: Interim analysis of immunogenicity, tumor control and survival. Annals of Oncology. 28. v523–v523. 12 indexed citations
10.
Attia, Steven, Vanessa Bolejack, Kristen N. Ganjoo, et al.. (2017). A phase II trial of regorafenib (REGO) in patients (pts) with advanced Ewing sarcoma and related tumors (EWS) of soft tissue and bone: SARC024 trial results.. Journal of Clinical Oncology. 35(15_suppl). 11005–11005. 29 indexed citations
11.
Kneisl, Jeffrey S., Myra Robinson, James T. Symanowski, et al.. (2017). The effect of radiation therapy in the treatment of adult soft tissue sarcomas of the extremities: a long‐term community‐based cancer center experience. Cancer Medicine. 6(3). 516–525. 9 indexed citations
12.
Tap, William D., Robin L. Jones, Brian A. Van Tine, et al.. (2016). Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. The Lancet. 388(10043). 488–497. 436 indexed citations breakdown →
13.
14.
Demetri, George D., Michael B. Livingston, Samir D. Undevia, et al.. (2015). 3436 Efficacy and safety of trabectedin (T) or dacarbazine (D) for treatment of patients (pts) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS) after prior chemotherapy. European Journal of Cancer. 51. S700–S700. 1 indexed citations
15.
Widemann, Brigitte C., Denise K. Reinke, Lee J. Helman, et al.. (2013). SARC006: Phase II trial of chemotherapy in sporadic and neurofibromatosis type 1 (NF1)-associated high-grade malignant peripheral nerve sheath tumors (MPNSTs).. Journal of Clinical Oncology. 31(15_suppl). 10522–10522. 19 indexed citations
16.
Tap, William D., Brian Andrew Van Tine, Anthony Elias, et al.. (2012). A phase Ib/II study evaluating the efficacy of doxorubicin (D) with or without a human anti-PDGFRα monoclonal antibody olaratumab (IMC-3G3) in the treatment of advanced soft tissue sarcoma (STS).. Journal of Clinical Oncology. 30(15_suppl). TPS10099–TPS10099. 2 indexed citations
17.
Maki, Robert G., Mary Louise Keohan, Samir D. Undevia, et al.. (2008). Updated results of a phase II study of oral multi-kinase inhibitor sorafenib in sarcomas, CTEP study #7060. Journal of Clinical Oncology. 26(15_suppl). 10531–10531. 18 indexed citations
18.
Fowler, Daniel H., et al.. (1998). Non–Host-Reactive Donor CD8+ T Cells of Tc2 Phenotype Potently Inhibit Marrow Graft Rejection. Blood. 91(11). 4045–4050. 24 indexed citations
19.
Fowler, Daniel H., et al.. (1998). Non–Host-Reactive Donor CD8+ T Cells of Tc2 Phenotype Potently Inhibit Marrow Graft Rejection. Blood. 91(11). 4045–4050. 3 indexed citations
20.
Livingston, Michael B., et al.. (1987). Case Report: Fatal Cardiac Tamponade in a Young Man with Group C Streptococcal Endocarditis. The American Journal of the Medical Sciences. 294(5). 353–356. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Breelyn A. Wilky Breakdown of academic impact, for papers by Gina Z. D’Amato Breakdown of academic impact, for papers by Lorenzo D’Ambrosio Breakdown of academic impact, for papers by Binh Bui Nguyen Breakdown of academic impact, for papers by Martine Trassard Breakdown of academic impact, for papers by Veridiana Pires de Camargo Breakdown of academic impact, for papers by Jonathan Landa Breakdown of academic impact, for papers by Claudia Lebedinsky Breakdown of academic impact, for papers by Saskia Kropf Breakdown of academic impact, for papers by César Serrano
Rankless by CCL
2026